INTRODUCTION
The kidney continually monitors a wide variety of substances in the plasma and the forming urine in order to regulate the homeostatic balance of endogenous substances, as well as to promote the excretion of toxins. The pivotal role of the kidney in the maintenance of whole-body homeostasis is revealed in the pathophysiology of renal failure, in which key parameters of homeostasis are disrupted, including plasma levels of sodium, potassium, calcium, phosphate, and pH, as well as defects in red blood cell number and extracellular fluid volume. In order to function properly, the kidney must be able to accurately monitor the concentrations of a wide range of substances. To do this, the kidney employs a number of strategies, including one which has become recognized only recently: the role of 'sensory' receptors.
Recent studies have highlighted roles that sensory receptors -taste receptors, olfactory receptors (ORs), and G-protein coupled receptors of the orphan 'Gpr' family -play in a variety of tissues throughout the body. The ligands for these receptors are often chemicals already known to be essential to physiology [1, 2] , indicating that substances such as metabolites may serve signaling functions beyond their traditional roles [3] [4] [5] . For example, the PKD2L1-PKD1L3 complex is a pH sensor which is found both in the tongue and in the spinal column; and although it serves to sense pH in both environments, in the tongue it functions as the sour taste receptor and in the spinal column it acts to monitor the pH of the cerebrospinal fluid. Similarly, the bitter taste receptors found in the tongue are also present in the ciliated epithelium of the lung, in which they mediate bronchodilation and changes in ciliary beat frequency in response to inhaled receptor ligands [6, 7] . Likewise, sweet taste receptors play a role in the gut, in which they regulate glucose transport and neuroendocrine secretion [8, 9] . In addition to taste receptors, ORs also play important roles in mediating chemosensing in muscle [10] and sperm [11] , and recently we have reported that ORs also play a role in the kidney and cardiovascular system [12,13 & ] (reviewed in [14] and [15] ). In addition to taste receptors and ORs, orphan receptors of the 'Gpr' family (a subset of the G-protein coupled receptors superfamily 'Class A') are another large class of receptors which can serve 'sensory' functions. The Gpr receptors are orphan receptors with no known ligands -however, some recent studies have begun to deorphanize these receptors and delineate their functions, and it is becoming clear that these receptors play diverse roles in physiology in a wide variety of tissues. For example, Gpr30 acts as an estrogen receptor and plays a role in breast cancer [16, 17] , Gpr37 and Gpr37L1 are receptors for prosaptide which mediate protection against oxidative stress in astrocytes [18] , and Gpr56 is thought to play a role in cancer progression [19] . In addition, a subset of the Gprs have been found to play a role in sensing compounds related to metabolism [20] , including short-chain fatty acids (Gpr41 [21] [22] [23] [24] [25] and Gpr43 [21] [22] [23] ), medium-chain fatty acids (Gpr84, [20, 26] ), and long-chain fatty acids (Gpr40 [23, [27] [28] [29] , Gpr119 [20, 30] , and Gpr120 [28] ). Not surprisingly, many of these fatty acid-sensing Gprs play roles in metabolism in a variety of tissues (including the pancreas, central nervous system, gastrointestinal system, adipose tissue, and leukocytes and keratinocytes [20] ), and are being studied in the context of type 2 diabetes [27] [28] [29] [30] as well as inflammation [23, 26, 31] .
It is impressive to note that when receptor expression is assayed in an unbiased fashion, the Gpr receptors are often found to be quite highly expressed [32] . In contrast, however, the Gpr family is relatively understudied, due in large part to the fact that most Gpr receptors are orphans. Although one must appreciate the risk and difficulty of exploring the roles of receptors whose ligands and signaling pathways are unknown, it is unlikely that these receptors are well expressed in specific tissues without a purpose or function. Thus, it is both informative and necessary to begin to understand the roles of these novel receptors and pathways, and to expand the current repertoire of receptors studied in the kidney beyond the 'usual suspects.' It is our hope that by studying these receptors, we can gain novel and unexpected insights into renal physiology -indeed, recent studies have begun to greatly expand our knowledge in this area. In this review, we will highlight studies which have delineated exciting and novel roles for Gpr receptors in the kidney.
Gpr30 (G-protein coupled estrogen receptor 1)
Gpr30 (also known as GPER1 or G-protein coupled estrogen receptor 1) is an estrogen receptor which is thought to play a role in a subset of breast cancers [16, 17] . However, it has also been suggested that estrogen-Gpr30 interacts with the renin-angiotensin-aldosterone system, as well as nitric oxide signaling, to influence renal and cardiovascular physiology [33] . Furthermore, in studies beginning in about 2011, accumulating evidence has suggested that Gpr30 functions as a receptor for aldosterone in the vascular endothelium [34] [35] [36] [37] [38] , although there are dissenting views (summarized in [39] ). Although aldosterone is a steroid receptor, it has long been appreciated that this hormone also exhibits 'nongenomic' effects not attributable to its canonical nuclear receptor [40] . At least some of these vascular effects may in fact be mediated by Gpr30, although, as stated above, the data are not yet definitive.
With regards to the kidney specifically, a study by Hofmeister et al. in 2012 [41 & ] demonstrated that Gpr30 mediates the actions of estrogen in intercalated cells in isolated renal tubules. Estrogen, in common with aldosterone, is a steroid hormone which has also been appreciated as having 'nongenomic' effects. In these studies, the authors first demonstrated that Gpr30 mRNA is present in isolated murine DCT2/CNT/iCCD segments (distal convoluted tubule 2 or connecting tubule or initial cortical collecting duct). The authors then showed that estrogen caused an increase in intracellular calcium in intercalated cells in these tubules and that this effect was absent in tubules from Gpr30 knockout mice. In future studies, it will be important to determine whether Gpr30 -or other orphaned Gprs -may also be responsible for some
KEY POINTS
Gpr receptors are orphan receptors which are relatively understudied, but are being found to play important roles in a variety of tissues.
In the kidney, Gpr30 mediates nongenomic actions of estrogen in intercalated cells; Gpr30 has also been implicated in mediating nongenomic effects of aldosterone in the vasculature.
Gpr41 is a short-chain fatty acid receptor which plays a role in BP control.
Gpr48, also known as Lgr4, plays a role in renal development and also modulates the expression of the mineralocorticoid receptor.
Gpr91 is a succinate receptor which plays a role in BP control.
of the 'nongenomic' effects of aldosterone in the kidney.
Gpr41
Gpr41 and Gpr43 were identified as receptors for short-chain fatty acids (SCFAs) by two different groups in 2003 [21, 22] ; in addition, another G-protein coupled receptor (olfactory receptor 78; Olfr78 [13 & ]) has a similar ligand profile. Intriguingly, the primary source of SCFAs in the plasma is the gut microbiota [42] . SCFAs produced by microbiota metabolism interact with host receptors to modulate host physiology (e.g., host adiposity via Gpr41 activation [24] ).
Recently, Gpr41 was found to be expressed in the kidney and in blood vessels of the cardiovascular system by reverse transcriptase polymerase chain reaction (RT-PCR) [13 & ] -in addition, the two other SCFA receptors (Gpr43 and Olfr78) were also expressed in the kidney and cardiovascular system. It was reported that in wild-type mice, an intravenous dose of propionate produced a decrease in blood pressure (BP) (13.9 mmHg [13 & ]). However, this decrease was absent in Gpr41 -/-. These data indicate that Gpr41 mediates the hypotensive effects of propionate (thought to be due to changes in vascular resistance in the peripheral vasculature). In addition, it was found that this effect is also opposed by another SCFA receptor (Olfr78) [13 & ,15]. This study concluded that SCFAs interacted with these SCFA receptors to modulate host BP and that the bulk of the hypotensive response to propionate is mediated by Gpr41 (although Olfr78, and possibly Gpr43, also play roles to modulate the response). As described above, Gpr41 is also found in the kidney by RT-PCR in addition to expression in the cardiovascular system (as is Gpr43 and Olfr78). Although Olfr78 was localized to the renal afferent arteriole [13 & ] and reported to have a role in modulating renin release, the specific renal cell type in which Gpr41 and Gpr43 are localized has not yet been elucidated (although Gpr41 -along with Gpr43 and Olfr78 -was expressed in isolated juxtaglomeruli apparatus). In future studies, it will be important to precisely localize Gpr41 and Gpr43 within the kidney and to determine how these different SCFA receptors interact to modulate host BP responses.
Gpr48 (Lgr4; leucine-rich repeat-containing G-protein coupled receptor 4)
The most extensively studied renal Gpr is Gpr48, also referred to as Lgr4 (leucine-rich repeat-containing G-protein coupled receptor 4). Gpr48 tissue distribution has been examined by three different groups, using a variety of techniques, including northern blot [43] , murine gene trap [44] , and the use of a monoclonal antibody in both human and mouse tissues [46] . All three groups agree that, in addition to other tissues, Gpr48 is expressed in the kidney. In particular, Gpr48 localizes to the proximal and distal tubules, but not glomeruli [44, 45] , with a greater abundance in the cortex than in the medulla [45] . In 2011, three groups independently reported that Gpr48 (Lgr4) and its relative Lgr5 are receptors for R-spondins [46] [47] [48] , which are Wnt signaling agonists.
Several studies have implicated Gpr48 in renal development, and two different whole-animal knockout mice have been used to study Gpr48 in the kidney. Using the first knockout model, it was reported that Gpr48 knockout animals are born in lower than expected frequencies, and those animals which do survive to birth typically die by P2 with renal hypoplasia and elevated plasma creatinine [49] . (Interestingly, Gpr48 mice do not appear to nurse [49] , which likely contributes to neonatal death, and may be related to the expression of Gpr48 in the olfactory epithelium and vomeronasal organ [44] as nursing at birth is olfactory-dependent [50, 51] .) The authors also found that the ureteric bud in these animals undergoes premature differentiation, as evidenced by the premature expression of Dolichos biflorus agglutinin and aquaporin 3 in the ureteric bud of Gpr48 knockout mice at E15.5. This study was performed using mice on a mixed background; subsequently, the authors backcrossed the mice onto C57BL/6J and reported that on this background, the phenotype was even more severe. No Gpr48 knockout pups survived to birth [52] , and renal hypoplasia was evident in embryonic pups (E16.5). The authors looked at Gpr48 expression during embryogenesis using in-situ hybridization, and found that Gpr48 is expressed in renal vesicles and in progenitors of the tubule epithelium (including comma-shaped and S-shaped bodies) and that Gpr48 knockout mice exhibit impaired branching morphogenesis. In another follow-up study [53] , it was reported that apoptosis is increased in Gpr48 knockout kidneys and that the expression of the antiapoptotic paired box gene 2 (PAX2) is decreased. The authors suggest that an increase in apoptosis likely contributes to the renal hypoplasia seen in Gpr48 knockout animals.
In the original study examining the role of Gpr48 in renal development, it was found that one single Gpr48 knockout mouse lived beyond P2 and survived until P42. At death, this animal was found to have multiple, fluid-filled renal cysts (among other pathological findings) [49] . In agreement with this, another group reported that genetic deletion of Gpr48 induces renal cystic disease [54 & ]. For these studies, the authors used a different Gpr48 knockout [54 & ], which also has significant perinatal death (60% of pups died between P0 to P1). However, in this case the authors were able to generate Gpr48 knockout mice which were spared embryonic or neonatal death through breeding and crossbreeding. In these mice, they found that the kidney weight/body weight (KW/BW) ratios were consistently lower in Gpr48 knockout animals. Typically, one would expect animals with renal cystic disease to have a higher KW/BW ratio; however, presumably renal hypoplasia in these animals (reported in the other knockout model) results in a lower KW/BW ratio despite the apparent cystic burden. In sum, 67% of the Gpr48 knockout mice developed multiple renal cysts. Further analysis showed that both polycystin 1 and polycystin 2 expression was reduced in Gpr48 animals (polycystin 1 and polycystin 2 being the genes mutated in autosomal dominant polycystic kidney disease or ADPKD). In addition, b-catenin/ Wnt signaling (which has been implicated in PKD [55]) was elevated in Gpr48 knockout animals, indicating that the cysts seen in the Gpr48 knockout may be contributed to by alterations in polycystin 1 and polycystin 2, as well as alterations in b-catenin/ Wnt signaling.
Finally, Gpr48 has also been linked to the expression of the mineralocorticoid receptor [56 & ]. These studies were done using the second Gpr48 knockout described above; although 50% of the knockout mice died by P2 in this study, the authors were able to study the remaining knockout animals. When fed a low-salt diet, these mice were found to have a phenotype akin to a mild form of pseudohypoaldosteronism type I, including hyponatremia with salt loss and hyperkalemia, despite increased aldosterone (a milder phenotype was seen when mice were given normal sodium chow). In addition, Gpr48 knockout animals expressed lower levels of a-epithelial sodium channel (ENAC) and the Na þ /K þ ATPase, as well as lower levels of mineralocorticoid receptor. The authors went on to demonstrate that Gpr48 regulates mineralocorticoid receptor expression, and suggest that Gpr48 may be necessary for normal expression levels of mineralocorticoid receptor. In support of this, in 2013 it was reported [57 && ] that a nonsense mutation in Gpr48 in humans is associated with hyperkalemia and hyponatermia (among a variety of other phenotypes; no other renal phenotypes were reported).
Gpr91
Gpr91 was initially identified as a receptor for succinate in 2004 [3] . Succinate is an intermediate of the citric acid cycle, and as such is intimately woven into energy usage and metabolism. Although chiefly found in the mitochondria, succinate is also found in the plasma in the mm range [3] . In addition, there are physiological conditions (hypoxia, oxidative stress) under which succinate levels rise [58, 59] .
In the initial article in 2004, He et al. [3] reported the unexpected finding that succinate induces a hypertensive response in animals, which is Gpr91dependent. This BP effect is mediated by the reninangiotensin system, and [3] further studies demonstrated that this hypertension is caused by an increase in renin release, mediated by succinate activation of Gpr91 in the macula densa [5, 60] . These data imply that succinate 'sensing' may allow the kidney to monitor signs of renal energy deprivation and to increase BP (and renal perfusion) when these conditions occur.
Intriguingly, this previously unrecognized signaling pathway has now been found to play roles not only in physiology, but in pathophysiology as well. High-plasma glucose levels cause local increases in succinate levels which can promote renin release via Gpr91 [58, 61] . It is known that metabolic syndrome is often associated with the development of hypertension; these data provide a potential explanation for why increased plasma glucose levels may lead to hypertension. Along the same lines, it may be possible to utilize succinate as a biomarker for potential progression to diabetic nephropathy; indeed, succinate levels are elevated in the urine of diabetic mice [61] .
CONCLUSION
In summary, sensory receptors play a variety of important roles in traditionally 'nonsensory' organs. Recently, studies have outlined a number of novel roles for Gpr receptors in a variety of pathways in the kidney. In the future, it will be important to not only further investigate the functions of these receptors, but also to discover the full complement of Gpr receptors in the kidney and their functional roles.
